HSD17B13 and metabolic dysfunction-associated steatotic liver disease: When HSD17B13 was more highly impressed, it, both directly and indirectly, played pathogenic roles in the occurrence and development of NAFLD in vitro and in vivo, and thus down-regulating the high expression of HSD17B13 produced a therapeutic effect in NAFLD.